Gilead appoints new CFO

Gilead Sciences has appointed Andrew Dickinson, who currently serves as the company’s Executive Vice President, Corporate Development and Strategy, as Chief Financial Officer (CFO), effective November 1, while remaining a member of the senior leadership team, reporting to the Chairman and Chief Executive Officer.

Gilead said Tuesday in a press release that Dickinson joined the company in 2016 and has transformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making. He served as the architect of the company’s 2017 acquisition of Kite Pharma, Inc. and of the 10-year, global research collaboration with Galapagos NV announced earlier this year. In his new role, Dickinson will retain responsibility for the corporate development and strategy organization, Gilead said.

Daniel O’Day, Chairman and Chief Executive Officer, said: “Andy is an exceptional, highly strategic leader. In addition to his impressive business and financial acumen and broad experience, Andy possesses strong creativity and vision. This has been evident in the way Gilead has approached acquisitions and partnerships under Andy’s leadership,”

“Over the past months, one of my key priorities has been to ensure we have an outstanding team of leaders to shape Gilead’s long-term success. I am pleased that with Andy’s appointment as CFO, we now have our full leadership team in place.”

Dickinson said: “I am looking forward to working with the talented teams across Gilead in this new role as we together seek to improve care for millions of people around the world who are in need of better treatment options.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.